No headlines found.
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Globe Newswire (Fri, 14-Nov 7:00 AM ET)
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
Globe Newswire (Wed, 5-Nov 7:30 AM ET)
Globe Newswire (Mon, 3-Nov 9:15 AM ET)
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Globe Newswire (Mon, 6-Oct 7:31 AM ET)
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Marker Therapeutics trades on the NASDAQ stock market under the symbol MRKR.
As of December 22, 2025, MRKR stock price climbed to $1.42 with 440,382 million shares trading.
MRKR has a beta of 1.49, meaning it tends to be more sensitive to market movements. MRKR has a correlation of 0.11 to the broad based SPY ETF.
MRKR has a market cap of $23.68 million. This is considered a Sub-Micro Cap stock.
Last quarter Marker Therapeutics reported $1 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $510,000 and exceeded earnings estimates by $.28.
In the last 3 years, MRKR traded as high as $9.68 and as low as $.67.
The top ETF exchange traded funds that MRKR belongs to (by Net Assets): VTI, VXF.
MRKR has underperformed the market in the last year with a price return of -62.6% while the SPY ETF gained +17.1%. However, in the short term, MRKR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +57.8% vs +3.0% return in SPY. But in the last 2 weeks, MRKR shares have been beat by the market, returning 0.0% compared to an SPY return of +0.5%.
MRKR support price is $1.21 and resistance is $1.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRKR shares will trade within this expected range on the day.